导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.46% | 1219/4773 |
| 近一周 | -2.46% | 2241/5462 |
| 近一月 | -4.69% | 2655/5421 |
| 近一季 | -8.40% | 2797/5209 |
| 近半年 | -5.21% | 2781/4920 |
| 近一年 | 10.07% | 1030/4366 |
| 近两年 | 75.35% | 872/2954 |
| 近三年 | 41.70% | 682/2253 |
| 成立以来 | 86.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.46% 927/4961 |
19.38% 1301/5312 |
- - |
- - |
| 2025 | 32.08% 1201/4813 |
2.41% 1384/3635 |
2.12% 1837/4076 |
24.37% 1476/4524 |
1.54% 1344/4813 |
| 2024 | 7.41% 1663/3463 |
-2.46% 1363/2808 |
-4.93% 1591/3014 |
16.08% 1544/3129 |
-0.21% 1347/3463 |
| 2023 | -4.90% 702/2656 |
7.58% 552/2280 |
-3.82% 913/2385 |
-4.05% 1047/2515 |
-4.21% 912/2655 |
| 2022 | -17.16% 554/2207 |
-13.16% 707/1919 |
3.15% 1207/2016 |
-10.03% 339/2113 |
2.79% 831/2208 |
| 2021 | 20.31% 183/1822 |
-1.32% 468/1255 |
10.55% 453/1330 |
5.87% 251/1466 |
4.17% 360/1822 |
| 2020 | 25.54% 616/1250 |
-6.20% 468/1028 |
17.12% 391/1067 |
9.43% 650/1164 |
4.42% 841/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时中证500ETF联接C VS. 长安沪深300非周期A(740101) |